Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adjuvant Chemotherapy
12%
Advanced Urothelial Carcinoma
12%
Asia
12%
Cisplatin
12%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
12%
Erdafitinib
100%
Europe
12%
Fibroblast Growth Factor Receptor 1 (FGFR1)
50%
Growth Factor Receptor Tyrosine Kinase
12%
Hyponatremia
12%
Initial Part
25%
Locally Advanced
12%
Long Follow-up
25%
Long-term Efficacy
12%
Long-term Safety
12%
Medical Center
12%
Metastatic Urothelial Carcinoma
100%
Neoadjuvant Chemotherapy
12%
North America
12%
Objective Response Rate
25%
Once-daily
12%
One Dose
12%
Phase I Study
100%
Progressive Disease
12%
Receptor Tyrosine Kinase Inhibitor
12%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Safety Profile
25%
Stomatitis
12%
Systemic Chemotherapy
12%
Treatment-related Adverse Events
25%
Treatment-related Mortality
12%
Up-titration
12%
Medicine and Dentistry
Adjuvant Chemotherapy
12%
Adverse Event
25%
Chemotherapy
12%
Cisplatin
12%
Erdafitinib
100%
Fibroblast Growth Factor Receptor
50%
Hyponatremia
12%
Neoadjuvant Chemotherapy
12%
Oncology
12%
Oral
12%
Progressive Disease
12%
Protein Tyrosine Kinase
12%
Response Evaluation Criteria in Solid Tumors
12%
Stomatitis
12%
Transitional Cell Carcinoma
100%
Tyrosine-Kinase Inhibitor
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Chemotherapy Regimens
25%
Cisplatin
12%
Diseases
12%
Erdafitinib
100%
Fibroblast Growth Factor Receptor
50%
Hyponatremia
12%
Protein Tyrosine Kinase
12%
Protein Tyrosine Kinase Inhibitor
12%
Solid Malignant Neoplasm
12%
Stomatitis
12%
Transitional Cell Carcinoma
100%